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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by selective degeneration of
motoneurones. Familial ALS is an age-dependent autosomal dominant disorder in which mutations in the homodimeric
enzyme Cu/Zn superoxide dismutase 1 (SOD1) is linked to the disease. An animal model for this disease is a transgenic mouse
expressing the mutated human SOD1G93A gene. Recent electrophysiological data emphasised that the striking selective
vulnerability of motoneurones might be due to their differential calcium buffering capacities. Therefore we have investigated,
using immunohistochemistry, the expression of different calcium binding proteins in brainstem and spinal cord from normal
and SOD1 mutated mice. Among the 13 calcium-binding proteins screened, only one, S100A6, a homodimeric calcium-
binding protein able to bind four Zn2, appeared to be highly expressed in the SOD1 mutated mice. In brainstem, reactive
astrocytes, but not motoneurones, from several regions, including nerve 12 root, were highly S100A6-positive. Hypoglossal
nucleus was negative for S100A6. In dorsal root, reactive astrocytes from both white matter and anterior horn were highly
reactive. If overexpression of S100A6 is specific for ALS, it will be a valuable diagnostic marker for this disease. ß 2000
Elsevier Science B.V. All rights reserved.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurode-
generative disease characterised by selective moto-
neurone degeneration in brainstem, spinal cord,
and motor cortex [1]. Symptoms of ALS are muscle
atrophy, weakness and fasciculation. Besides moto-
neurone degeneration, atrophy of ventral roots, cor-
ticospinal tract degeneration, somatic and axonal in-
clusions of aberrant neuro¢lament proteins and
astrogliosis occurred. The incidence of ALS is ap-
proximately 1/10 000. In familial ALS cases, 20%
are linked to approximately 40 di¡erent identi¢ed
mutations in the Cu/Zn superoxide dismutase
(SOD1) gene [2,3]. To investigate structural changes
on the molecular level, transgenic mice model carry-
ing an additional copy of the mutant human SOD1
0167-4889 / 00 / $ ^ see front matter ß 2000 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 0 0 ) 0 0 1 0 1 - 4
Abbreviations: MdV, medullary reticular nucleus, ventral
part ; 12n, root of hypoglossal nerve; IRt, intermediate reticular
nucleus; mlf, medial longitudinal fasciculus; ts, tectospinal tract;
ml, lemniscus; ROb, raphe obscurus nucleus
* Corresponding author. Fax: +32-2-555-6285;
E-mail : rpochet@ulb.ac.be
BBAMCR 14685 27-11-00 Cyaan Magenta Geel Zwart
Biochimica et Biophysica Acta 1498 (2000) 264^272
www.elsevier.com/locate/bba
gene were established. These mice develop similar
pathology of motoneurones that resembles human
motoneurone disease [3^5]. In the present study, we
used the mouse model TgN SOD1G93A introduced by
Gurney et al. [6] to investigate the molecular basis of
the selective vulnerability of motoneurones. Trans-
genic mice express high levels of human SOD1 con-
taining a substitution of glycine to alanine at posi-
tion 93, a change that has little e¡ect on enzyme
activity but caused motoneurone disease [7]. In this
case, a ‘gain of function’ mechanism of the mutant
SOD1-gene is thought to contribute to the pathogen-
esis of motoneurone degeneration. In agreement with
this model, mice became paralysed in one or more
limbs as a result of motoneurone loss from the spinal
cord and died by 5 to 6 months of age.
Calcium signalling plays a major role as a messen-
ger for di¡erent signal cascades including apoptosis
and neuronal cell death. During normal physiologi-
cal activity, motoneurones show substantial calcium
elevations in somatic and dendritic compartments
[8,9]. Peak elevations in [Ca]i were found to reach
the micromolar concentration domain during bursts
of 10^15 action potentials [10,11]. Investigations us-
ing patch-clamp and micro£uorimetric measurements
indicated that brainstem motoneurones in compari-
son to other neurones have a low capacity to bu¡er
calcium in the cell soma most likely as a result of low
calcium-binding protein expression [12,13]. This spe-
cialisation of brainstem motoneurones makes them
particularly sensitive to disturbed calcium homeosta-
sis which may explain their vulnerability.
In this work we investigated the di¡erential expres-
sion of 13 calcium-binding proteins in normal and
mutated mice. We discovered that one of them,
S100A6 (calcyclin), was overexpressed in reactive as-
trocytes from the mutated mice.
The zinc- and calcium-binding protein S100A6 has
a molecular mass of 10 kDa and two distinct EF-
hand domains that bind Ca2 [14]. S100A6, in vitro,
interacts with target proteins such as tropomyosin
[15], annexins II and XI [16,17] and caldesmon [18].
S100A6 has a calcium-dependent dual localisation at
nuclear envelope and plasma membrane as well as an
increase of translocation into a network structure
around the nucleus [19,20]. S100A6 is also overex-
pressed in tumours like acute myeloid leukaemia
[21], in neuroblastoma and in melanoma cell lines.
S100A6 is expressed in astrocyte subpopulations in
rat [22] and in human [23].
Although ALS is known as a motoneurone dis-
ease, astrocytes are important actors in the pathol-
ogy. In general, CNS responds to any neuronal in-
juries by an increase in number and size of astrocytes
expressing GFAP (so-called reactive astrocytes)
[24,25]. In humans su¡ering from ALS, astrogliosis
was seen in the cerebral cortex [26] and in cervical
and lumbar levels of spinal cord [27]. In ALS, gluta-
mate transfer is impaired. Astrocytes play an impor-
tant role for such transport and maintain glutamate
in the synaptic cleft at low levels. In this work we
con¢rm astrogliosis in the ALS animal model and
further show that a zinc/calcium-binding protein
(S100A6) is overexpressed in astrocytes.
2. Materials and methods
2.1. Animals
For our investigations we used transgenic animals
(purchased from the Jackson Laboratory, ME, USA)
heavily su¡ering from motor dysfunction and normal
animals of equal age as control. Animal experiments
were carried out in accordance with the guidelines of
the Ethics Committee of the Medical Faculty of the
University of Go«ttingen. Transgenic male mice were
obtained either from strain B6SJL-TgN (SOD1G93A)
1 Gur or B6SJL-TgN (SOD1G93A) 1 Gur dl. Males
were mated with normal female mice (strain:
B6SJLF1) to get heterozygote animals for investiga-
tion. The strain indicated as dl had a reduced copy of
the mutated human superoxide dismutase gene and
therefore showed a delayed onset of the ALS pheno-
type. In this strain, ¢rst signs of the disease appear
after 246 days ( þ 32 days). Progression of the disease
is then very rapid and after approximately 2 weeks
animals were killed because of their disability of in-
gestion.
2.2. Identi¢cation of transgenic animals using
diagnostic polymerase chain reaction (PCR)
Transgenic animals were identi¢ed using a diag-
nostic PCR method. After approximately 246 days
of life, motor dysfunction was monitored and a piece
BBAMCR 14685 27-11-00 Cyaan Magenta Geel Zwart
D. Hoyaux et al. / Biochimica et Biophysica Acta 1498 (2000) 264^272 265
of the mouse tail was dissected, resuspended in diag-
nostic bu¡er (20 mM Tris^HCl (pH 8.4), 50 mM
KCl, 0.45% NP40, 0.45% Tween-20) and homoge-
nised. Proteinase K was added for at least 2 h at
55‡C. Afterwards the homogenate was heated for
10 min at 95‡C and centrifuged at 1000Ug for
1 min. One Wl from the supernatant was used for PCR.
Special primers (oIMR113 5P-CAT CAG CCC
TAA TCC ATC TGA-3P and oIMR114 5P-GTA
GGT GGA AAT TCT AGT ATC ATC C-3P) were
used to amplify a 236 bp product from exon 4 of the
human SOD1 gene within the transgene construct.
To verify that the PCR performed on normal animal
was also successful, speci¢c primers (oIMR042: 5P-
CTA GGC CAC AGA ATT GAA AGA TCT-3P
and oIMR043 5P-GTA GGT GGA AAT TCT
AGC ATC ATC C-3P) were used amplifying a
324 bp product from the endogenous Il-2 gene. Mas-
termix (Quiagen, Hilden, Germany), primers, ultra-
clean water and DNA were mixed. PCR was per-
formed using 94‡C 4 min for initial denaturation,
35 cycles (92‡C for 1 min/60‡C for 1 min/72‡C for
1 min) and a ¢nal elongation of 5 min at 72‡C. Ten
Wl of each ampli¢cation product was run on a 2%
agarose gel in parallel with a molecular mass marker
(100 bp ladder, MBI Fermentas, Vilnus, Lithuania),
and stained with ethidium bromide (Fig. 1).
2.3. Fixation of tissue
Mice were anaesthetised and transcardially per-
fused using 100 mM phosphate-bu¡ered saline
(PBS) (pH 7.4) for 2 min to wash out the blood,
followed by a solution of 4% bu¡ered paraformalde-
hyde in 0.2 M phosphate bu¡er (pH 7.4) for at least
15 min. Spinal cord and brainstem were dissected
and post-¢xed for at least 4 h with PAF 4%. They
were rinsed for 1 day in 0.1 M PBS (pH 7.4) and
dehydrated in alcohol 70‡ (24 h), 90‡ (24 h) and 100‡
(24 h). Afterwards they were immersed in toluol
(16 h) and included in para⁄n. Five-Wm sections
were used for immunohistochemistry.
2.4. Immunohistochemistry
Speci¢c polyclonal antibody raised in goat against
human recombinant S100A6 was previously charac-
terised [29]. Brain sections were depara⁄nated and
rehydrated in alcohol (100‡ and 90‡). Endogenous
peroxidase activities were minimised by incubation
in a solution of methanol with 1% H2O2 at room
temperature for 30 min. Slides were rinsed under
continue £ow of water during 10 min, in distilled
water and in 50 mM Tris-bu¡ered saline (TBS) (pH
7.4). Non-speci¢c labelling of the secondary antibody
was blocked by incubating the sections at 37‡C with
5% horse normal serum (Vector Laboratories) for
30 min. The primary antibody was incubated at
4‡C overnight. The S100A6 antibody was diluted at
1/10 000 in a TBS solution with bovine serum albu-
min (3%). Slides were incubated with the biotinylated
anti-goat antibody (1/100) for 30 min. Staining was
done with avidin^biotin^peroxidase complex (ABC)
kit reagents (Vector Laboratories) with diaminoben-
zidine/H2O2 as the chromogenic substrates. Some
sections were counterstained with cresyl violet for
identi¢cation of intact cell bodies.
3. Results
Mice carrying an additional mutated human
SOD1G93A gene were identi¢ed using PCR method
with speci¢c primers for SOD1 gene and a murine
Il-2 gene as a positive PCR-control (Fig. 1). PCR
showed clearly the existence of the Il-2 murine gene
in every mouse investigated. As predicted by the mat-
ing strategy approximately 50% of the o¡spring were
SOD1G93A-positive. The veri¢cation was successful
Fig. 1. PCR gel. Lanes 1 and 10, molecular mass marker (bp
size: 80, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1031);
lanes 2, 4, 7, 8: transgenic mice; lanes 3, 5, 6: normal mice;
lane 9, control (primers without DNA).
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for both very young animals and those which are
heavily su¡ering of motor disorders. We observed
no motor disorders in animals tested negative for
the mutated human SOD1 G93A gene. The ampli¢ed
fragment of the Il-2 murine gene is larger than the
fragment for the SOD1 gene and settled ¢rst after gel
electrophoresis. According to the basepair ladder
supplied by Fermentas, the size for the fragments
of 346 bp and 236 bp respectively, was con¢rmed.
As a negative control in every PCR experiment one
assay lacking mouse DNA was added (Fig. 1, lane
9).
S100A6 immunohistochemistry showed labelling in
both normal and SOD1G93A-positive animals. In nor-
Fig. 2. S100A6 immunohistochemistry of mice spinal cord (A,B) and brainstem (C,D) counterstained with cresyl violet. Normal mice
(A,C); SOD1 mutated mice (B,D). S100A6 is restricted to few astrocytes in normal mice whereas S100A6 is overexpressed in both
white matters and anterior horns of SOD1 mutated mice (B). Reactive astrocytes are heavily labelled (D). Scale bars: A,B = 200 Wm;
C,D = 20 Wm.
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mal animals, few labelled cells, both in the spinal
cord (Fig. 2A) and brainstem (Fig. 2C), could be
observed. In spinal cord, positive S100A6 cells that
were present in both white matter and grey matter
are astrocytes. In SOD1G93A-positive animals the la-
belling was conspicuously more intense compared to
normal animals. S100A6 was signi¢cantly overex-
pressed in both white and grey matter of the spinal
cord (Fig. 2B) and in some brainstem areas (Fig.
2D). In the grey matter glial cells located in the an-
terior horn were S100A6-positive (Fig. 2B). Higher
magni¢cation clearly showed the typical shape of
astrocytes with their bipolar organisation surround-
ing neurones and vessels (Fig. 2C). In the mutated
Fig. 3. GFAP (A^D) and S100A6 (E,F) immunohistochemistry of brainstem from normal (A,C,E) and SOD1 mutated (B,D,F) mice.
Reactive astrocytes are numerous in SOD1 mutated mice (B,D), positive for GFAP (B,D) and S100A6 (F). Scale bars: A,B = 200 Wm;
C^E = 60 Wm; F = 40 Wm.
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mice, S100A6-positive astrocytes had a typical mor-
phology of reactive astrocytes with conspicuous pro-
cesses (Fig. 2D). Heavy S100A6 immunoreactivity
for astrocytes was observed in the following brain-
stem areas: MdV, 12n, IRt, mlf, ts, ml and ROb. In
the hypoglossal nucleus essentially no S100A6-posi-
tive labelled astrocytes were detected. To con¢rm the
astrocytic cell type, we used GFAP immunohisto-
chemistry in normal (Fig. 3A,C) and SOD1 mutated
mice (Fig. 3B,D). Sections from normal animals
showed light labelling whereas SOD1 animals
showed astrogliosis with heavy labelling. Speci¢city
of the immunohistochemistry was controlled using
the S100A6 antibody (1/10 000) preincubated over-
night with pure S100A6 (1 Wg/ml). When spinal
cord and brainstem sections were incubated with
Fig. 4. S100A6 immunohistochemistry of spinal cord (A,B) and brainstem (C,D) from SOD1 mutated mice. Preincubation of S100A6
antibody with pure S100A6 eliminated the labelling (B,D). Scale bar = 200 Wm.
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the mixture (antibody+antigen), no staining could be
detected (Fig. 4B,D).
4. Discussion
The exact reason for selective impairment of mo-
toneurones during the neurodegenerative disease
ALS is still not well understood. Besides impairments
in intracellular protein transport or glutamate expo-
sure (excitotoxicity), many results support the idea
that cellular calcium overload is a key component
to neuronal impairment [30,31]. Our previous results
showing that vulnerable motoneurones, in compari-
son to surviving motoneurones, have a low calcium
bu¡ering capacity [10,12,13], are convergent with
such a notion. This led us to investigate di¡erent
calcium-binding proteins in brainstem and spinal
cord and examine if this disease has modi¢ed their
expression in motoneurones. Surprisingly, our immu-
nohistochemical screening using calbindin, calmodu-
lin, parvalbumin, S100A1, S100A2, S100A3, S100A4,
S100A5, S100A6, S100A8, S100A9, S100A12 and
S100B antibodies showed that (1) only S100A6 was
overexpressed in brainstem and spinal cord of trans-
genic mice and (2) the modi¢cations occurred in re-
active astrocytes and not in motoneurones.
It is known that astrogliosis is observed in a vari-
ety of conditions in which neuronal injuries are in-
duced and that astrocytes play a role in mediating
neuronal degeneration. More speci¢cally in SOD1
mutated mice, astrogliosis is one of the earliest
pathological changes observed [32,33]. In humans, a
widespread astrogliosis exists in the subcortical white
matter from ALS patients [34], and a close temporal
correlation between the onset of neuronal degenera-
tion and the beginning of astrogliosis has been dem-
onstrated [35]. Also, a selective loss of glial glutamate
transporter in ALS was described [36]. Recently,
Trotti et al. [28] demonstrated that SOD1 mutant
selectively inactivated a glial glutamate transporter
required to inactivate the synaptic action of gluta-
mate. Astrocytes can also release glutamate in a cal-
cium-dependent manner [37]. The reason for the
striking upregulation of S100A6, a protein whose
gene belongs to a cluster of 15 S100 genes located
on chromosome 1q21, is not clear. The exact in vivo
functions of S100 proteins are not yet elucidated but
some of them are implicated in the regulation of
protein phosphorylation, enzyme activities, Ca2 ho-
meostasis, and the dynamics of microtubules and
type III intermediate ¢laments [38]. Interestingly,
S100A6, which forms homodimers, binds four Zn2
and therefore may be an important actor in the de-
velopment of ALS. Catalytic activities of Cu/Zn for
dismutation of the superoxide radical into H2O2 or
O2 requires enzyme-bound copper which alternates
between reduced (Cu1) and oxidised (Cu2) forms
during two asymmetric catalysis steps. Loss of zinc
diminishes superoxide scavenging and increases tyro-
sine nitration by SOD [39] and alters the coordina-
tion of Cu. Mutated SOD1 have a lower a⁄nity for
Zn2 [40] allowing rapid reduction of mutant SOD1
to the Cu1 form. The reduced SOD1 mutant would
then run the normal catalytic step backwards, con-
verting oxygen to superoxide and promote intracel-
lular damage. Overexpression of S100A6, a zinc-
binding protein, would contribute to the depletion
of Zn in astrocytes and in motoneurones and accel-
erate cell damage.
Whether S100A6 is exclusively upregulated in
astrocytes from ALS is not known, but it is poten-
tially an interesting tool as a marker, for ALS
in particular, for neurodegenerative diseases in gen-
eral.
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